Mobile technology to connect patients to remote doctors

Country of origin | United States of America

Health problem addressed
The bottom of the pyramid population in the developing world continues to face fundamental challenges in healthcare, due to lack of access, low affordability, low quality and exploitative care, and a reactive, emergency-driven system. Existing solutions lack financial and human resources and show sub-optimal use of limited resources.

Product description
This product is an Integrated Mobile Health Technology Platform that enables frontline health providers (community health workers, rural nurses and doctors) to connect patients to remote doctors in order to obtain timely medical diagnosis and administer effective treatment for underserved patients. Selected awards: Winner at the 2008 MIT 100K Entrepreneurship Competition and Best Telemedicine Innovation at the 2009 World Health Care Congress.

Product functionality
Frontline health providers use the mobile application to perform health risk screening and medical triage to identify health concerns. The diagnostics application on the phone instructs health providers with immediate actions to care for the patient, or transmits the case to remote doctors for further diagnosis and treatment advice.

Developer’s claims of product benefits
This solution is cost-effective as it requires no additional equipment or infrastructure by using available mobile phones, mobile connectivity and local health providers. Training for local health providers takes less than an hour because all users are already familiar with the use of mobile phones. Maintenance is minimal as local phone stores are capable of maintaining the mobile devices. The service reduces travel costs, minimizes time to obtain treatment (from weeks to minutes), and is accessible locally to underserved patients via health workers or close-by rural clinics.

Operating steps
Frontline health providers use mobile phones to access the diagnostics application. They enter patient symptoms information by going through a series of decision-tree based medical algorithm. For cases requiring remote doctor consultation, the phone transmits the patient symptoms information via mobile broadband or SMS/MMS to the remote doctor.

Development stage
The product was technically evaluated and tested for clinical effectiveness via concordance rates between in-person and mobile-transmitted remote diagnosis in Egypt, Ghana, Botswana, the US. We pursue various partnerships. Partners include mHealth Alliance, BRAC, Sajida Foundation, Mobinil Egypt, Orange Botswana, University of Pennsylvania Medical School, Harvard, MIT, American Academy of Dermatology.

Future work and challenges
These applications and corresponding business models were tested through pilots in over 10 countries. The basic technology proposition was proven and patient acceptability demonstrated. Commercial scalability is now ready to be tested by 1) improving the technology platform to support large scale usage from current ~500,000 beneficiaries to >1 million, 2) expanding distribution channels, 3) refining service models to suit our markets.

User and environment
User: Patient, family member, nurse, midwife, physician
Training: 30-60 min walk-through of the mobile application
Maintenance: Technician, engineer, manufacturer

Environment of use
Requirements: Mobile connectivity, access to a power source to charge mobile phones.

Product specifications
Dimensions (mm): 110 x 47 x 14 (approx.)
Weight (kg): 0.008
Life time: Varies by phone model
Retail Price (USD): Varies
Year of commercialization: 2009
Currently sold in: US, Botswana, Bangladesh
Disclaimer

Eligibility for inclusion in the compendium has been evaluated by EuroScan member agencies, WHO Collaborating Centres, and WHO. However, the evaluation by EuroScan member agencies, WHO Collaborating Centres, and WHO has been solely based on a limited assessment of data and information submitted in the developers’ applications and, where available, of additional sources of evidence, such as literature search results or other publicly available information. There has been no rigorous review for safety, efficacy, quality, applicability, nor cost acceptability of any of the technologies. Therefore, inclusion in the compendium does not constitute a warranty of the fitness of any technology for a particular purpose. Besides, the responsibility for the quality, safety and efficacy of each technology remains with the developer and/or manufacturer. The decision to include a particular technology in the compendium is subject to change on the basis of new information that may subsequently become available to WHO.

WHO will not be held to endorse nor to recommend any technology included in the compendium. Inclusion in the compendium solely aims at drawing stakeholders’ attention to innovative health technologies, either existing or under development, with a view to fostering the development and availability of, and/or access to, new and emerging technologies which are likely to be accessible, appropriate and affordable for use in low- and middle-income countries.

WHO does not furthermore warrant or represent that:

1. the list of innovative health technologies is exhaustive or error free; and/or that
2. the technologies which are included in the compendium will be embodied in future editions of the compendium; and/or that
3. the use of the technologies listed is, or will be, in accordance with the national laws and regulations of any country, including but not limited to patent laws; and/or that
4. any product that may be developed from the listed technologies will be successfully commercialized in target countries or that WHO will finance or otherwise support the development or commercialization of any such product.

WHO disclaims any and all liability and responsibility whatsoever for any injury, death, loss, damage, use of personal data, or other prejudice of any kind whatsoever that may arise as a result of, or in connection with, the procurement, distribution and/or use of any technology embodied in the compendium, or of any resulting product and any future development thereof.

Developers whose technology has been included in the compendium shall not, in any statement of an advertising, commercial and/or promotional nature, refer to their participation and/or inclusion in the compendium. In no case shall the latter use the WHO name and/or the emblem, or any abbreviation thereof, in relation to their business or otherwise.